Qsymia sera

Now that First Manhattan Co. is gaining control of Vivus Inc.'s board and the top management job, all eyes will be on whether the dissident shareholder's team can ramp up sales of obesity drug Qsymia. Neither party is talking after their proxy settlement, but incoming CEO Anthony Zook has a commercial background.